In order to verify whether SAA1 is a potential prognostic factor in ccRCC patients, we compared the prognostication performance of the above traditional clinicopathologic features (including age, T stage, N stage, M stage, grade, tumor size, and immune therapy molecular PD-L1) and our biomarker SAA1. This evidence concerns the gene CD274 and neoplasm.